Hi Dr. T: Thanks for your great work. Can you speculate on how GLP-1 medications impact Parkinson’s when they don’t cross the blood brain barrier? Are there any other connections between, say, gut biome neurology, and extrapyramidal function? Thanks- Greg Sazima, MD
Yes, as Dan Drucker conveyed (in the companion podcast) from his experimental model work and that of others there is crosstalk from the gut to brain without invoking direct GLP-1 neuronal interaction for suppression of brain inflammation.
The shortage of these medications is getting pretty intense, with many of my patients scrambling to find refills and many having to stop cold turkey. The good clinical news keeps coming, and I believe the theoretical increased risk of pancreatic cancers has not materialized. Still waiting on definitive news about thyroid tumors, though this also seems unlikely outside of rat trials.
Some serious GI side effects for many, but also some serious success stories for many more.
Bravo indeed to these individuals, as these meds are now a commonplace in primary care treatment repertoires.
I had cold-turkey cutoff three times in the past 12 months. the complicated world of pharmacy distribution, pharma manufacturing and the overextend hypes of quick-fix social influencers.
Hi Dr. T: Thanks for your great work. Can you speculate on how GLP-1 medications impact Parkinson’s when they don’t cross the blood brain barrier? Are there any other connections between, say, gut biome neurology, and extrapyramidal function? Thanks- Greg Sazima, MD
Yes, as Dan Drucker conveyed (in the companion podcast) from his experimental model work and that of others there is crosstalk from the gut to brain without invoking direct GLP-1 neuronal interaction for suppression of brain inflammation.
The shortage of these medications is getting pretty intense, with many of my patients scrambling to find refills and many having to stop cold turkey. The good clinical news keeps coming, and I believe the theoretical increased risk of pancreatic cancers has not materialized. Still waiting on definitive news about thyroid tumors, though this also seems unlikely outside of rat trials.
Some serious GI side effects for many, but also some serious success stories for many more.
Bravo indeed to these individuals, as these meds are now a commonplace in primary care treatment repertoires.
I had cold-turkey cutoff three times in the past 12 months. the complicated world of pharmacy distribution, pharma manufacturing and the overextend hypes of quick-fix social influencers.
exactly. putting out fires like this all day every day in primary care. usually I can't help either. it is really bad right now!